Dacron vs Dardik for Fem-Pop Bypass (DaDa)

This study has been completed.

Sponsor:

Information provided by:

Radboud University

ClinicalTrials.gov Identifier:

NCT00523263

First received: August 30, 2007

Last updated: NA

Last verified: August 2007

History: No changes posted

Purpose

Clinical trial for the comparison of long-term patency of heparin-bonded Dacron and human umbilical vein vascular prostheses in above-knee femoro-popliteal bypass surgery.

Condition	Intervention	Phase
Intermittent Claudication Arterial Occlusive Diseases Atheroslerosis	Device: heparin-bonded and collagen coated polyster Device: Human umbilical vein femoro-popliteal bypass	Phase 3


Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Heparin Bonded and Collagen Coated Polyester or Human Umbilical Vein for Femoropopliteal Bypass: a Prospective Randomised Multicentre Trial.

Resource links provided by NLM:

MedlinePlus related topics: Blood Thinners

U.S. FDA Resources

Further study details as provided by Radboud University:

Primary Outcome Measures:

Primary and primary-assisted bypass patency [ Time Frame: 1 - 5 yrs ]

Secondary Outcome Measures:

Secondary bypass patency [ Time Frame: 1 - 5 yrs ]


Study Start Date:	January 1996
Study Completion Date:	April 2007

Arms	Assigned Interventions
Active Comparator: Dacron Patients receiving polyester above-knee femoro-popliteal bypass	Device: heparin-bonded and collagen coated polyster femoro-popliteal bypass
Active Comparator: HUV patients receiving HUV femoro-popliteal bypass	Device: Human umbilical vein femoro-popliteal bypass

Eligibility


Ages Eligible for Study:	31 Years to 89 Years (Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

age 31 to 89
intermittent claudication
ABI below 0.8

Exclusion Criteria:

non elective surgery
life expectancy below 2 yrs
contraindication for anticoagulant therapy

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00523263

Locations


Netherlands
Radboud UMCN, Dept Vascular Surgery
Nijmegen, Netherlands, 6500 HB

Sponsors and Collaborators

Radboud University

Investigators


Principal Investigator:	J. Adam van der Vliet, MD, PhD	Radboud University Medical Center Nijmegen

More Information

Publications:

Scharn DM, Oyen WJ, Klemm PL, Verhofstad AA, van der Vliet JA. Thrombogenicity and related biological properties of heparin bonded collagen coated polyester and human umbilical vein prosthetic vascular grafts. J Surg Res. 2006 Aug;134(2):182-9. Epub 2006 Mar 20.

Scharn DM, Oyen WJ, Klemm PL, Wijnen MH, vanderVliet JA. Assessment of prosthetic vascular graft thrombogenicity using the technetium-99m labeled glycoprotein IIb/IIIa receptor antagonist DMP444 in a dog model. Cardiovasc Surg. 2002 Dec;10(6):566-9.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Dirven M, Scharn DM, Blankensteijn JD, van der Vliet JA. Preservation for future use of the autologous saphenous vein during femoro-popliteal bypass surgery is inexpedient. Eur J Vasc Endovasc Surg. 2008 Oct;36(4):420-3. doi: 10.1016/j.ejvs.2008.06.012.


ClinicalTrials.gov Identifier:	NCT00523263 History of Changes
Other Study ID Numbers:	DaDa-trial
Study First Received:	August 30, 2007
Last Updated:	August 30, 2007
Health Authority:	Netherlands: Medical Ethics Review Committee (METC)

Additional relevant MeSH terms:


Intermittent Claudication Arterial Occlusive Diseases Arteriosclerosis Vascular Diseases Cardiovascular Diseases Signs and Symptoms	Calcium heparin Heparin Anticoagulants Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 28, 2016

To Top